What’s Ahead for BeiGene, Ltd. (BGNE) After Touching 52-Week High?

May 22, 2018 - By Stephen Andrade

BeiGene, Ltd. (NASDAQ:BGNE) Logo

The stock of BeiGene, Ltd. (NASDAQ:BGNE) hit a new 52-week high and has $209.57 target or 8.00 % above today’s $194.05 share price. The 7 months bullish chart indicates low risk for the $10.42B company. The 1-year high was reported on May, 22 by Barchart.com. If the $209.57 price target is reached, the company will be worth $833.36 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.44% or $0.85 during the last trading session, reaching $194.05. About 82,415 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 354.57% since May 22, 2017 and is uptrending. It has outperformed by 343.02% the S&P500.

Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on August, 8. They expect $-2.13 EPS, down 40.13 % or $0.61 from last year’s $-1.52 per share. After $-2.03 actual EPS reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts 4.93 % negative EPS growth.

More notable recent BeiGene, Ltd. (NASDAQ:BGNE) news were published by: Globenewswire.com which released: “BeiGene Reports First Quarter 2018 Financial Results” on May 09, 2018, also Nasdaq.com with their article: “BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer” published on May 17, 2018, Streetinsider.com published: “BeiGene (BGNE) Commences Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian …” on May 17, 2018. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) were released by: Nasdaq.com and their article: “These Stocks Have Quadrupled in Just 1 Year” published on May 19, 2018 as well as Seekingalpha.com‘s news article titled: “3 Things In Biotech, May 20: You Want Some Good News?” with publication date: May 21, 2018.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $10.42 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

BeiGene, Ltd. (NASDAQ:BGNE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: